Regorafenib in Patients with Antiangiogenic‐Naïve and Chemotherapy‐Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.

Authors: Riechelmann, Rachel P., Leite, Luiz S., Bariani, Giovanni M., Glasberg, Joao, Rivelli, Thomas G., da Fonseca, Leonardo Gomes, Nebuloni, Daniela R., Braghiroli, Maria I., Queiroz, Marcelo A., Isejima, Alice M., Kappeler, Christian, Kikuchi, Luciana, Hoff, Paulo M.

Source: Oncologist; Sep2019, Vol. 24 Issue 9, p1180-1187, 8p, 2 Charts, 2 Graphs

Subject Terms: HYPERTENSION risk factors, NEOVASCULARIZATION inhibitors, CANCER chemotherapy, CLINICAL trials, COLON tumors, CONFIDENCE intervals, NONPROFIT organizations, RECTUM tumors, TUMOR classification, PROTEIN-tyrosine kinase inhibitors, TREATMENT effectiveness, DISEASE progression, HYPOPHOSPHATEMIA, HAND-foot syndrome, TUMOR grading, DISEASE risk factors, THERAPEUTICS